flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 Patients with type 2 #diabetes and chronic disease are at high risk for kidney failure, cardiovascular events, and death. ⁣ ⁣ Whether treatment with would mitigate these risks is unknown. ⁣ ⁣ Preventing chronic kidney disease and

Food and Drug Administration (FDA) to treat Type 2 diabetes mellitus and lower the risk of heart attack or stroke in people with Type 2 diabetes and cardiovascular disease

some clients may also experience mild water retention or joint stiffness

Key Differences Summary# Conclusion# The comparison between liraglutide and semaglutide illustrates the progress within the GLP-1 receptor agonist class

Mayo Clinic notes that general recommendations are to consume 15 to 30 grams of protein at each meal

In the trial STEP 1, people who took semaglutide lost an average of 15% to 17% of their body weight over 68 weeks, compared to 2.4% for those who took a placebo